Comparative Pharmacology
Head-to-head clinical analysis: NEOTRIZINE versus PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOTRIZINE versus PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE.
NEOTRIZINE vs PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neotrizine contains sulfadiazine, a competitive inhibitor of dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic, and sedative. Dextromethorphan is a cough suppressant that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
NEOTRIZINE (sulfamethoxazole/trimethoprim) 800 mg/160 mg orally every 12 hours for 5-14 days, depending on indication.
For cough and upper respiratory symptoms: 5 mL (containing promethazine hydrochloride 6.25 mg and dextromethorphan hydrobromide 15 mg) orally every 4 to 6 hours, not to exceed 30 mL in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours in adults with normal renal function; in renal impairment, half-life may extend to 12-18 hours requiring dose adjustment.
Promethazine: 10-19 hours (mean 12 hours). Dextromethorphan: extensive metabolizers (CYP2D6) 3-5 hours; poor metabolizers 20-30 hours. Clinical context: accumulation with repeated dosing, especially in poor metabolizers.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal elimination accounts for 20-30%, with the remainder as metabolites.
Promethazine: primarily hepatic metabolism, renal excretion of metabolites (~70%, <1% unchanged); fecal excretion (20-30%). Dextromethorphan: hepatic metabolism, renal excretion of metabolites and <1% unchanged drug.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic